Argitalpenak (122) JUAN JOSÉ TORRADO DURÁN argitalpenak

2023

  1. Application of Accelerated Predictive Stability Studies in Extemporaneously Compounded Formulations of Chlorhexidine to Assess the Shelf Life

    Molecules, Vol. 28, Núm. 23

  2. Design, synthesis and biological evaluation of antiparasitic dinitroaniline-ether phospholipid hybrids

    Bioorganic Chemistry, Vol. 138

  3. Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with Leishmania infantum

    Antibiotics, Vol. 12, Núm. 2

  4. Guiding Clinical Prescription of Topical Extemporaneous Formulations of Sodium Cromoglycate Based on Pharmaceutical Performance

    Pharmaceutics, Vol. 15, Núm. 6

  5. Melatonin as Modulator for Sulfur and Nitrogen Mustard-Induced Inflammation, Oxidative Stress and DNA Damage: Molecular Therapeutics

    Antioxidants, Vol. 12, Núm. 2

  6. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2022

  1. Drug Stability: ICH versus Accelerated Predictive Stability Studies

    Pharmaceutics, Vol. 14, Núm. 11

  2. Effect of Primary Packaging Material on the Stability Characteristics of Diazepam and Midazolam Parenteral Formulations

    Pharmaceutics, Vol. 14, Núm. 10

  3. In Vitro and In Vivo Characteristics of Olive Oil as Excipient for Topical Administration

    Pharmaceutics, Vol. 14, Núm. 12

  4. Leishmania infantum infection does not affect the main composition of the intestinal microbiome of the Syrian hamster

    Parasites and Vectors, Vol. 15, Núm. 1

  5. Tailoring Rational Manufacturing of Extemporaneous Compounding Oral Dosage Formulations with a Low Dose of Minoxidil

    Pharmaceutics, Vol. 14, Núm. 3

2021

  1. Antileishmanial drug discovery and development: Time to reset the model?

    Microorganisms, Vol. 9, Núm. 12

  2. Desarrollo de una IVIVC basada en disolución dinámica en el aparato USP IV aplicada a diferentes formulaciones de Montelukast

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 241-242

  3. One and two-step in vitro-in vivo correlations based on usp iv dynamic dissolution applied to four sodium montelukast products

    Pharmaceutics, Vol. 13, Núm. 5

2020

  1. Antifungal and antiparasitic drug delivery

    Pharmaceutics, Vol. 12, Núm. 4

  2. Effect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compaction

    Chirality, Vol. 32, Núm. 2, pp. 185-190

  3. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

2019

  1. Discovery and Pharmacological Studies of 4-Hydroxyphenyl-Derived Phosphonium Salts Active in a Mouse Model of Visceral Leishmaniasis

    Journal of Medicinal Chemistry, Vol. 62, Núm. 23, pp. 10664-10675

  2. Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics

    European Journal of Medicinal Chemistry, Vol. 183

  3. Increased efficacy of oral fixed-dose combination of amphotericin b and ahcc® natural adjuvant against aspergillosis

    Pharmaceutics, Vol. 11, Núm. 9